CD8A and neoplasm: While anti-TIGIT monotherapy or combination therapy with anti–PD-1 has shown potential in some clinical trials, these approached remain insufficient to fully reinvigorate CD8+ T cells, particularly in patients with advanced or high tumor burden (61, 62).